Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A C-H bond activation strategy based on electrochemical activation of a metal hydride is introduced. Electrochemical oxidation of (
t
Bu
4
PCP
)IrH
4
(
t
Bu
4
PCP
is [1,3-(
t
Bu
2
PCH
2
)-C
6
H
3
]
-
) in the presence of pyridine derivatives generates cationic Ir hydride complexes of the type [(
t
Bu
4
PCP
)IrH(L)]
+
(where L = pyridine, 2,6-lutidine, or 2-phenylpyridine). Facile deprotonation of [(
t
Bu
4
PCP
)IrH(2,6-lutidine)]
+
with the phosphazene base
tert
-butylimino-tris(pyrrolidino)phosphorane,
t
BuP
1
(pyrr), results in selective C-H activation of 1,2-difluorobenzene (1,2-
DFB
) solvent to generate (
t
Bu
4
PCP
)Ir(H)(2,3-C
6
F
2
H
3
). The overall electrochemical C-H activation reaction proceeds at room temperature without need for chemical activation by a sacrificial alkene hydrogen acceptor. This rare example of undirected electrochemical C-H activation holds promise for the development of future catalytic processes.
...
PMID:Electrochemical C-H bond activation
via
cationic iridium hydride pincer complexes. 3211 Feb 95
